Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 21, 2007. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding the company's Ordinary Shares and American Depositary Receipts (ADRs).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory notification of share transactions rather than a financial performance report.
Material Changes
The filing details a specific transaction on March 20, 2007, where Abacus (GSK) Trustees Limited, acting as trustee for the GlaxoSmithKline Employee Trust, transferred 2,578 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991. The company was advised of these transactions on March 21, 2007.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly addresses compliance with Disclosure Rule 3.1.4R(1)(b) regarding the notification of the share transfer.
Investor Verification Points
- Verify the impact of the 2,578 share transfer on the total outstanding share count.
- Confirm the specific identities of the SmithKline Beecham Employee Share Option Plan 1991 participants receiving the shares.
- Review the status of the GlaxoSmithKline Employee Trust and its holdings relative to the company's total equity.
- Note that three directors (Dr J-P Garnier, Dr M M Slaoui, and Mr J S Heslop) hold interests in the trust shares as potential beneficiaries alongside other employees.